From: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
First Author, Year, Study Place | Data Collection | Study Design | Sample Size | Groups being Compared | RR/HR, (95% CI), P-Value | Conclusion | Variables Adjusted for |
---|---|---|---|---|---|---|---|
Riedinger JM, 2008, France [64] | 1996 to 2000 | Multicentric Retrospective study | 130 | ≤ 20 kU/L, > 20 kU/L | 4.18 (2.65-6.62), < 0.0001 | Nadir concentration, residual tumor volume and number of chemotherapy courses were found to be independent prognostic factors for disease free survival and overall survival | Chemotherapy courses, residual tumor |
Riedinger JM, 2006, France [38] | 1988 to 1996 | Multicentric retrospective study | 631 | ≤ 20 kU/L, > 20 kU/L | 1.65 (1.28-2.12), < 0.0001 | CA125 half life and nadir concentration are powerful independent prognostic factors. CA125 nadir concentration and time to nadir all had a univariate prognostic value for disease free survival and overall survival | Age, FIGO stage, residual tumor, CA125 half life |
Crawford SM, 2005, [8] | 1988 to 2000 | Retrospective study | 79 | ≤ 10 U/ml, 11--20 U/ml, 21--30 U/ml | NA, < 0.001 | The nadir group was the only predictor of overall survival that remained very highly significant (P < 0.001) after the effect of the other factors was allowed for | Type of chemotherapy, CA125 level at course three |
Gard GB, 1994, Australia [70] | 1985 to 1991 | Retrospective study | 223 | > 35 U/ml, 15-35 U/ml, < 15 U/ml | Uni- 3.23 (2.62-3.99), < 0.0001 Multi-0.85 (0.54-1.33), 0.476 | The initial CA125 level and nadir CA125 level, although significant when considered alone, were not significant independent variables | Tumor types, FIGO stage, residual disease, CA125 |